ArticleGastroenterology report2026
Prediction of endoscopic postoperative recurrence in Crohn's disease: a nationwide multicenter real-world cohort from China.
Article in Gastroenterology report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preventing endoscopic postoperative recurrence (ePOR) remains a major challenge in Crohn's disease (CD). This study aimed to identify the clinical and histopathological predictors of CD ePOR. Methods: This nationwide, multicenter retrospective cohort study included 389 CD patients from five tertiary Chinese IBD centers, all of whom underwent curative ileocolonic resection between July 2016 and June 2024. The primary endpoint was ePOR at 6-12 months after surgery, defined as a modified Rutgeerts' score of ≥ i2b. Prediction models were developed based on the result of multivariate analysis of clinical and pathological data. Results: The overall ePOR rate was 24.9%. Multivariate analysis showed that prior exposure to biologics [odds ratio (OR) 2.695, 95% confidence interval (CI) 1.605-4.525, Conclusions: In the era of biologics and perioperative optimization, the 6-12-month ePOR rate among CD patients was 24.9%. A combined clinical-pathological model showed strong predictive performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.